Myelofibrosis Care: Pharmacist Role and Treatment Challenges

Opinion
Video

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and a panel of pharmacists explore pharmacist roles in myelofibrosis care, treatment challenges, patient outcomes, and pharmacist responsibilities within interdisciplinary teams.

This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In a Pharmacy Times® Peer Exchange led by Mahmoudjafari, a panel, including Davis and Nachar, discuss the pharmacist’s role in myelofibrosis care. Davis outlines challenges faced by patients with myelofibrosis, emphasizing symptoms and the impact on survival. The conversation focuses on the treatment landscape, highlighting Janus kinase inhibitors’ role and associated anemia challenges, leading to treatment discontinuation in over 30% of cases. Nachar adds insights into multifactorial anemia causes and treatment options, including androgens, immunomodulatory agents, and the recently approved momelotinib. The historical use of blood cell transfusions is also mentioned. This concise exchange underscores pharmacists’ crucial role in addressing myelofibrosis challenges and the evolving treatment strategies.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Video 15 - "Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM  "
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 11 - "Complying with REMS Training and Documentation Requirements"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Related Content
© 2024 MJH Life Sciences

All rights reserved.